GBA Presents: House of Gummy-!

stonedinvestor said:
1> Mind Medicine says MM120 showed statistically significant efficacy in Phase 2 » 08:22 MNMD

2> Twist Bioscience price target raised by $3 at JPMorgan, » 10:29 TWST
More...





TWSTTwist Bioscience Corporation is frisky!

$44.15 +2.94(+7.13%)10:13 AM 05/06/24
NASDAQ |$USD |Realtime
 
WWW Wolverine World Wide, Inc.

$11.45 +0.70(+6.51%)10:13 AM 05/06/24

Remember the rule of 3> We have two positive mentions in the past few days we need one more catalyst...
 
stonedinvestor said:
For now we can use SIMO in replacement for HWM
SIMO Silicon Motion Technology Corporation

$73.38-0.02(-0.03%)2:06 PM 05/03/24

It seems to me a very good earn report:

Silicon Motion raises FY24 revenue view to $800M-$830M, consensus $793.3M »18:05
SIMO


Silicon Motion sees Q2 revenue $199M-$208M, consensus $187.1M »18:03
SIMO


Silicon Motion reports Q1 EPS 64c, consensus 57c »18:03
SIMO

SIMO Silicon Motion Technology Corporation- STOCK OF THE WEEK
$73.57 0.17(+0.23%)2:09 PM 05/03/24
NASDAQ |$USD |Realtime
More...







STOCK OF THE WEEK SOARS!

SIMO Silicon Motion Technology Corporation

$80.70 +6.75(+9.12%)10:16 AM 05/06/24
NASDAQ |$USD |Realtime
 
stonedinvestor said:
Common sense says we will get some upgrades Monday on SIMO... oh wait one just came in.

Mr Woo!

Analyst Simon Woo of Bank of America Securities reiterated a Buy rating on Silicon Motion (SIMO – Research Report), with a price target of $90.00. Simon Woo has given his Buy rating due to a combination of factors pertaining to Silicon Motion's promising performance and growth potential.
More...




TY WOO!!
 
stonedinvestor said:
Twist Bioscience (TWST) is another stock breaking out:
twst1600-300x169.png

Twist Bioscience (NASDAQ:TWST) operates in the biotech industry and focuses on synthesizing DNA.

TWST guidance for 2024. It expects significant growth in 2024, aiming for total revenue between $288 million and $293 million, reflecting an 18% to 20% increase. This top-line swelling is expected to be seen in its key operating segments. Namely, SynBio’s revenue is projected to grow by 16% to 19%. NGS revenue by 21% to 23%. Biopharma revenue is expected to see about 3% growth.
More...





YUP!

AN OLD FRIEND MYO IS GETTING A LUMP SUM PAYMENT.- NOT SURE THE AMMT

MYO Myomo, Inc.

$4.25 +0.49(+13.03%)10:21 AM 05/06/24
 
You must log in or register to reply here.
Back
Top